Back to Search
NICHOLAS HORVATH, PHARMD
PHARMD
Pharmacist
NPI: 1205438132Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
23557(MD)
Research & Publications (20)
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
PMID 19656151·Br J Haematol·2009
3-trial
Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
PMID 19371392·Intern Med J·2009
4-observational
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
PMID 19273705·J Clin Oncol·2009
2-rct
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
PMID 19220531·Intern Med J·2009
6-review
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
PMID 19147779·Clin Cancer Res·2009
4-observational
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
PMID 19011760·Invest New Drugs·2009
3-trial
Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
PMID 18284457·Intern Med J·2008
4-observational
Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients.
PMID 18026147·Bone Marrow Transplant·2008
8-other
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
PMID 17679727·J Clin Oncol·2007
3-trial
Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma.
PMID 17145816·Clin Cancer Res·2006
8-other
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma.
PMID 17107908·Leuk Lymphoma·2006
3-trial
Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
PMID 16775651·Support Care Cancer·2006
3-trial
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
PMID 15778725·Bone Marrow Transplant·2005
3-trial
Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
PMID 15086696·Intern Med J·2004
8-other
Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
PMID 14660049·Cytotherapy·2003
3-trial
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.
PMID 14500379·Cancer Res·2003
8-other
Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential.
PMID 12827617·Hum Pathol·2003
8-other
Isolated cardiac recurrence of acute lymphoblastic leukemia characterized by t(11;19) two years after unrelated allogeneic bone marrow transplantation.
PMID 12393287·Cancer Genet Cytogenet·2002
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 405 N CENTER ST
WESTMINSTER, MD 21157 - Phone
- (410) 857-6320
Quick Facts
- NPI
- 1205438132
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile